Clinical Study

Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome

Table 6

Risk of metabolic disorders in women with PCOS divided into 4 phenotypical groups (A, B, C, D) based on biochemical, hormonal and proper indexes.

Phenotypical groupABCD
Oligo + HA + PCOOligo + HAHA + PCOOligo + PCO

Fasting insulin (uU/mL) πŸ• , πŸ” πŸ• Β± 5 , 4 9 πŸ— , πŸ• 𝟏 Β± 4 , 3 9 πŸ– , 𝟐 πŸ“ Β± 3 , 3 3 πŸ– , πŸ“ 𝟎 Β± 6 , 3 6
Insulin after 30 min of OGTT πŸ’ πŸ• , πŸ“ πŸ— Β± 2 4 , 2 0 πŸ— πŸ• , πŸ’ πŸ‘ Β± 5 7 , 0 8 πŸ” πŸ’ , πŸ– πŸ– Β± 2 8 , 1 9 πŸ– πŸ’ , 𝟎 𝟎 Β± 1 9 , 8 0
Insulin after 60 min of OGTT πŸ” 𝟏 , 𝟎 πŸ’ Β± 4 6 , 0 2 πŸ• 𝟏 , 𝟐 πŸ— Β± 2 9 , 1 2 πŸ“ 𝟏 , πŸ– πŸ– Β± 4 2 , 3 1 πŸ— πŸ• , 𝟎 𝟎 Β± 9 , 9 0
Insulin after 120 min of OGTT πŸ’ πŸ‘ , 𝟐 𝟐 Β± 4 3 , 7 5 πŸ‘ πŸ• , 𝟏 πŸ’ Β± 2 9 , 6 2 𝟐 𝟐 , πŸ– πŸ– Β± 1 3 , 2 4 πŸ• πŸ” , πŸ“ 𝟎 Β± 3 3 , 2 3
Fasting Glucose (mg/dL) πŸ– πŸ• , πŸ” πŸ– Β± 1 1 , 9 4 πŸ– 𝟐 , πŸ‘ πŸ• Β± 1 0 , 4 5 πŸ– πŸ’ , πŸ’ 𝟎 Β± 8 , 9 3 πŸ– 𝟎 , 𝟎 𝟎 Β± 7 , 0 7
Glucose in 30 min of OGTT 𝟏 πŸ’ 𝟐 , πŸ• 𝟎 Β± 2 0 , 3 8 𝟏 πŸ‘ 𝟐 , πŸ’ 𝟎 Β± 2 6 , 2 0 𝟏 𝟐 𝟎 , 𝟏 𝟎 Β± 3 2 , 7 0 𝟏 πŸ‘ πŸ’ , πŸ“ 𝟎 Β± 7 , 7 8
Glucose in 60 min of OGTT 𝟏 𝟐 πŸ— , πŸ” πŸ“ Β± 4 7 , 2 4 𝟏 𝟎 πŸ• , 𝟏 πŸ• Β± 1 3 , 1 9 πŸ— πŸ’ , πŸ” πŸ– Β± 3 5 , 1 1 𝟏 πŸ‘ πŸ” , 𝟎 𝟎 Β± 1 1 , 3 1
Glucose in 120 min of OGTT 𝟏 𝟎 πŸ“ , πŸ‘ πŸ– Β± 3 8 , 5 3 πŸ— 𝟐 , πŸ” πŸ• Β± 3 9 , 2 2 πŸ– πŸ” , πŸ— πŸ‘ Β± 1 6 , 9 0 𝟏 𝟏 πŸ’ , 𝟎 𝟎 Β± 7 , 0 7
HOMA-IR index 𝟏 , πŸ• πŸ• Β± 1 , 4 9 𝟐 , 𝟎 πŸ’ Β± 0 , 9 3 𝟏 , πŸ• πŸ– Β± 0 , 8 0 𝟏 , πŸ• πŸ‘ Β± 1 , 4 0
HOMA-Ξ² index 𝟏 𝟏 𝟎 , πŸ– πŸ— Β± 5 5 , 2 3 𝟏 πŸ” πŸ• , 𝟏 πŸ’ Β± 8 0 , 7 1 𝟏 𝟐 πŸ– , πŸ• πŸ– Β± 3 4 , 2 5 𝟏 πŸ” πŸ• , 𝟎 𝟏 Β± 6 5 , 6 1
QUICK index 𝟎 , πŸ‘ πŸ– Β± 0 , 0 5 𝟎 , πŸ‘ πŸ“ Β± 0 , 0 3 𝟎 , πŸ‘ πŸ” Β± 0 , 0 2 𝟎 , πŸ‘ πŸ• Β± 0 , 0 5
Peptide C (ng/mL) 𝟐 , 𝟎 πŸ— Β± 0 , 8 6 𝟐 , πŸ’ 𝟐 Β± 1 , 0 5 𝟏 , πŸ“ πŸ– Β± 0 , 8 7 𝟐 , πŸ– πŸ’ Β± 0 , 2 0
HsCRP (mg/L) 𝟐 , 𝟎 𝟎 Β± 1 , 8 1 𝟏 , πŸ• πŸ” Β± 1 , 5 6 𝟏 , πŸ“ 𝟎 Β± 1 , 0 8 𝟐 , πŸ“ πŸ— Β± 0 , 2 4
Cholesterol (mg/dL) 𝟏 πŸ– πŸ’ , 𝟐 πŸ‘ Β± 3 3 , 8 6 𝟏 πŸ” πŸ— , πŸ” πŸ• Β± 2 0 , 0 3 𝟏 πŸ” πŸ” , πŸ• 𝟎 Β± 1 2 , 2 8 𝟏 πŸ“ πŸ— , 𝟎 𝟎 Β± 3 8 , 1 8
HDL (mg/dL) πŸ” 𝟏 , πŸ• πŸ’ Β± 1 7 , 6 0 πŸ” πŸ’ , 𝟐 πŸ’ Β± 2 9 , 7 7 πŸ“ πŸ— , πŸ– 𝟏 Β± 1 5 , 5 9 πŸ“ πŸ— , πŸ— 𝟎 Β± 1 , 9 8
LDL (mg/dL) 𝟏 𝟎 πŸ‘ , 𝟏 πŸ’ Β± 2 9 , 3 5 πŸ– πŸ• , πŸ” πŸ’ Β± 2 6 , 1 4 πŸ— 𝟐 , πŸ’ πŸ‘ Β± 1 4 , 0 2 πŸ– 𝟏 , 𝟎 𝟎 Β± 2 4 , 0 4
Trigliceryde (mg/dL) πŸ— πŸ” , πŸ” πŸ’ Β± 5 6 , 7 8 𝟏 𝟎 πŸ• , 𝟏 πŸ‘ Β± 6 5 , 5 6 πŸ– 𝟎 , πŸ‘ πŸ‘ Β± 3 6 , 7 3 πŸ— 𝟐 , 𝟎 𝟎 Β± 6 2 , 2 3
BMI (kg/m2) 𝟐 πŸ” , 𝟐 𝟐 Β± 7 , 1 𝟐 πŸ– , πŸ— πŸ“ Β± 7 , 2 𝟐 πŸ” , 𝟏 𝟐 Β± 6 , 5 𝟐 πŸ– , πŸ‘ πŸ– Β± 8 , 6
BMI < 20%15,38%14,29%12,5%0
BMI 20–25%34,62%14,29%50,0%50,0%
BMI 25–30%26,92%28,57%12,5%0
BMI > 30%23,08%42,86%25,0%50,0%